ClinicalTrials.Veeva

Menu

Ultrasound Guided Single Shot Block of Posterior Tibial Nerve for Postoperative Pain Relief After Hallux Valgus Surgery

D

Dr.med. Sabine Schoenfeld

Status and phase

Unknown
Phase 4

Conditions

Hallux Valgus

Treatments

Drug: Ropivacaine 0,75%
Procedure: posterior tibial nerve block
Drug: morphine and droperidol

Study type

Interventional

Funder types

Other

Identifiers

NCT02282956
EKSG 13/126

Details and patient eligibility

About

Hallux surgery is known to be extremely painful. Standard pain therapy is treatment with NSAID and opioid painkillers. Patients are frequently not-satisfied with this. Some institutions use a nerve block (single shot or catheter technic) of the ischiadic nerve. But this procedure is invasive, has a potential risk of nerve lesion, and is not accepted by all surgeons. A single shot nerve block of the posterior tibial nerve is less invasive and could be superior compared to standard pain treatment. A great variability of nerve supply of the foot is well described. There are some hints that the posterior tibial nerve supplies the first metatarsal bone and the first metatarsal joint. A nerve block could reduce postoperative pain in hallux surgery. To assess the effectiveness of this investigated measure, the requested morphine dose of a PCA pump will be used to verify the effectiveness of the tibial nerve block.

Full description

The overall purpose is to evaluate the effectiveness of tibial nerve block for postoperative pain relief after hallux surgery. The primary objective is to assess the morphine requirement in the first 24 hours after surgery. Secondary objectives are maximum pain scores and sleeping quality in the postoperative period. Patient's satisfaction with the pain therapy and approximately nerve block duration will be asked in the final interview.

Primary study endpoint is a 50% reduction of morphine requirement with a 60% standard deviation within 24 hours after surgery. Power is 80%, the level of significance is set at 5% (p < 0,05).

Secondary endpoints are sleeping quality and maximum pain scores (maximum VAS) measured by means of postoperative questionnaire.

Enrollment

60 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age over 18 years
  • Elective Hallux valgus surgery ("Magerl" operation technique)

Exclusion criteria

  • Patient refusal, pregnancy
  • Regular medication with opioids
  • Drug abuse
  • Contraindication for regional anesthesia
  • Known allergy against one of the study drugs
  • Polyneuropathia, or any other neurodegenerative disorders

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

60 participants in 2 patient groups

study group
Experimental group
Description:
single shot, posterior tibial nerve block with 5 ml of Ropivacaine 0,75% before surgery postoperative PCA pump with morphine and droperidol (DHBP®) for the next 24 hours.
Treatment:
Drug: morphine and droperidol
Procedure: posterior tibial nerve block
Drug: Ropivacaine 0,75%
controll Group
Other group
Description:
After surgery: standard analgesic treatment by PCA (patient controlled analgesia) pumps with morphine and Droperidol (DHBP®) for the next 24 hours.
Treatment:
Drug: morphine and droperidol

Trial contacts and locations

1

Loading...

Central trial contact

Sabine Schoenfeld, MD; Volha Berning, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems